Impact of SARS-CoV-2 (COVID-19) Infection, Treated in Ambulatory Care, on Long-term Quality of Life in a Parisian Military Population

NCT ID: NCT04893070

Last Updated: 2022-10-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

173 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-15

Study Completion Date

2022-07-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In April 2020, a meta-analysis on the long-term sequelae of respiratory syndromes related to seasonal coronaviruses (SARS and MERS) showed a significant alteration in quality of life, with in particular a decrease in physical and emotional capacities and a deterioration of social life. An improvement of the quality of life is evidenced after 6 months but without reaching the level usually observed in healthy people. The impact of SARS-CoV-2 infection on quality of life can be explained by the persistence of pleomorphic symptoms in the medium to long term. In the military population, the majority of SARS-CoV-2 cases present minor to moderate forms of the disease. Military personnel have living conditions that differ from those of the general population, in particular because of their geographic mobility, which may be responsible for isolation from the family. This isolation can be regular (we speak of "geographical celibacy" when the soldier is posted in a geographical area far from the family unit) and/or occasional, during missions on the national territory or outside. This singularity justifies a study on the impact of SARS-CoV-2 (COVID-19) infection on the quality of life in this specific population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV2 Infection Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COVID+

Questionnaires on COVID-19 symptomatology and quality of life

Questionnaires COVID+

Intervention Type OTHER

* 1 questionnaire on COVID-19 symptomatology and quality of life 12 months after COVID-19 first symptoms
* 1 questionnaire on quality of life 18 months after COVID-19 first symptoms

COVID-

Questionnaires on quality of life

Questionnaires COVID-

Intervention Type OTHER

* 1 questionnaire on quality of life at enrollment
* 1 questionnaire on quality of life 6 months after enrollment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaires COVID+

* 1 questionnaire on COVID-19 symptomatology and quality of life 12 months after COVID-19 first symptoms
* 1 questionnaire on quality of life 18 months after COVID-19 first symptoms

Intervention Type OTHER

Questionnaires COVID-

* 1 questionnaire on quality of life at enrollment
* 1 questionnaire on quality of life 6 months after enrollment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Military personnel
* COVID+: diagnosed with COVID-19 and managed in ambulatory care since March 14th, 2020
* COVID-: not having been infected with SARS-CoV-2

Exclusion Criteria

* Hospitalized for COVID-19
* Having received a treatment against COVID-19 (other than paracetamol)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Direction Centrale du Service de Santé des Armées

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1er Centre Médical des Armées

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-A01038-33

Identifier Type: OTHER

Identifier Source: secondary_id

2020-COVID19-38

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Long Term Outcomes of Patients With COVID-19
NCT04360538 ACTIVE_NOT_RECRUITING
Long Term Impact of COVID-19
NCT05813574 COMPLETED